JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson's Janssen Says Phase 3b Trial of Active Psoriatic Arthritis Treatment Met Primary Endpoint

12/03/2021 | 09:51am EDT


© MT Newswires 2021
All news about JOHNSON & JOHNSON
05/19The Janssen Pharmaceutical Companies - New Data Show TREMFYA (guselkumab) Binds to Both..
AQ
05/19New Janssen Campaign Developed by and for the LGBTQ+ Community Inspires Action and Empa..
AQ
05/18Thinking about trading options or stock in Costco, Dollar Tree, Micron, Upstart, or Joh..
PR
05/17FDA Expands Authorization of Pfizer Covid Booster to Kids 5 to 11
DJ
05/17Citigroup Adjusts Price Target on Johnson & Johnson to $205 From $210, Reiterates Buy R..
MT
05/16Mariners put RHP Steckenrider on restricted list, add Elías
AQ
05/13Idaho announces $119 million opioid crisis settlement
AQ
05/13What We're Reading This Week
AQ
05/12Johnson & Johnson to Participate in Goldman Sachs 43rd Annual Global Healthcare Confere..
PR
05/12Africa's Covid-19 Vaccine Production Line in Jeopardy
AQ
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 96 248 M - -
Net income 2022 23 016 M - -
Net cash 2022 8 885 M - -
P/E ratio 2022 19,5x
Yield 2022 2,56%
Capitalization 458 B 458 B -
EV / Sales 2022 4,66x
EV / Sales 2023 4,43x
Nbr of Employees 141 700
Free-Float 84,2%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 173,94 $
Average target price 186,82 $
Spread / Average Target 7,41%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON2.59%457 706
PFIZER, INC.-14.23%284 192
ABBVIE INC.12.05%268 106
ROCHE HOLDING AG-16.41%265 188
ELI LILLY AND COMPANY3.64%257 689
NOVO NORDISK A/S-0.56%236 239